• GS-441524 (SKU B8461): Best Practices for Antiviral Assays

  2026-05-27

  This article addresses recurring challenges in cell-based antiviral research, focusing on the use of GS-441524 (SKU B8461) as a high-purity, reproducible nucleoside analog solution. Each scenario-driven Q&A illustrates how GS-441524 from APExBIO streamlines assay design, enhances data interpretation, and supports robust pharmacokinetic workflows, making it a reliable choice for biomedical researchers.

• Catalpol’s Neuroprotection in Alzheimer’s: Insights for Barr

  2026-05-27

  The reference study systematically reviews catalpol’s multifaceted neuroprotective effects in Alzheimer’s disease, emphasizing its anti-inflammatory and antioxidative mechanisms. Its approach offers a framework for understanding how natural compounds can modulate disease-relevant pathways, with implications for translational research in inflammation-driven disorders.

• MG-132 in Cancer Redox Biology: From Proteasome Inhibition t

  2026-05-26

  Explore how MG-132 (Z-LLL-al) advances cancer research by bridging proteasome inhibition, oxidative stress, and ferroptosis sensitivity. This in-depth article reveals new intersections between apoptosis, redox regulation, and innovative therapeutic strategies using MG-132.

• Lung-Targeted Risedronate Sodium/Vitamin D3 Dendrimers for O

  2026-05-26

  This study establishes a lung-targeted delivery system using PAMAM-G5 dendrimers conjugated with Risedronate Sodium and Vitamin D3 for enhanced osteoporosis management. The approach improves bioavailability, normalizes bone mineral density and serum biomarkers, and elucidates WNT-signaling modulation, offering a significant advance over conventional oral dosing.

• VDR Activation Limits Cisplatin-Induced AKI by Inhibiting Fe

  2026-05-25

  This study reveals that vitamin D receptor (VDR) activation protects against cisplatin-induced acute kidney injury (AKI) by suppressing ferroptosis via regulation of GPX4 expression. These findings clarify a mechanistic link between ferroptotic cell death and renal damage, opening new avenues for therapeutic intervention in drug-induced AKI.

• PINK1/Park2 Mitophagy as a Therapeutic Target in NAFLD Model

  2026-05-25

  Han et al. reveal that enhancing Park2-mediated mitophagy reverses mitochondrial dysfunction and lipid accumulation in non-alcoholic fatty liver disease (NAFLD) models. Their work uncovers mechanistic links between the PINK1/Park2 pathway and NAFLD progression, suggesting new therapeutic avenues for metabolic liver disease.

• Annexin V-Cy5/DAPI Apoptosis Kit: Precision in Cell Death As

  2026-05-24

  The Annexin V-Cy5/DAPI Apoptosis Kit empowers researchers to rapidly and reliably distinguish apoptotic from necrotic cells, streamlining cell death studies even in challenging disease models. Its robust sensitivity and dual-marker strategy enable high-confidence results in translational and mechanistic workflows where clarity counts.

• Trelagliptin Promotes Osteoblast Differentiation via RUNX2 U

  2026-05-23

  The referenced study uncovers a novel role for Trelagliptin, a DPP-4 inhibitor, in enhancing osteoblastic differentiation by upregulating RUNX2 through the AMPK pathway. These findings suggest a potential therapeutic application of Trelagliptin in osteoporosis, with implications for bone metabolism research and drug development.

• AG-126 (Tyrphostin AG-126): Reliable ERK1/2 Inhibition for C

  2026-05-22

  This article addresses real-world challenges in cell viability and signaling assays, demonstrating how AG-126 (Tyrphostin AG-126, SKU C4338) provides reproducible and selective ERK1/2 inhibition. Scenario-driven guidance links assay optimization, data interpretation, and product selection with evidence-backed best practices for biomedical researchers.

• 4-Hydroxytamoxifen: Practical Use in Cancer and Cardiac Rese

  2026-05-22

  4-Hydroxytamoxifen is a potent estrogen receptor modulator designed for applications in breast cancer, prostate cancer, and cardiac myocyte studies. Its high purity and DMSO-only solubility profile address the need for selective receptor modulation in non-aqueous workflows, but it is unsuitable for protocols requiring ethanol or water solubility.

• Chloroquine Diphosphate: Autophagy Modulation in Cancer Rese

  2026-05-21

  Chloroquine diphosphate is a potent autophagy modulator and TLR7/TLR9 inhibitor with defined roles in cancer research. It sensitizes tumor cells to therapy by disrupting autophagic flux and cell cycle progression. This article details its mechanisms, benchmarks, and proper integration for translational workflows.

• Lysoptosis: Serpin-Moderated Lysosome-Dependent Cell Death U

  2026-05-21

  The reference study reveals lysoptosis as a distinct, evolutionarily conserved form of lysosome-dependent cell death, characterized by lysosomal membrane permeabilization and cathepsin release in the absence of intracellular serpins. This work clarifies the role of cysteine proteases in regulated cell death and informs the application of cysteine protease inhibitors such as E-64d in mechanistic cell death research.

• Pterostilbene Enhances Mitophagy to Delay Dermal Fibroblast

  2026-05-20

  Zhou et al. (2025) demonstrate that pterostilbene mitigates senescence in human dermal fibroblasts by restoring mitochondrial function through enhanced mitophagy. This work provides mechanistic insight into skin aging and offers a research framework for targeting mitochondrial quality in anti-aging interventions.

• Red Blood Cell Lysis Buffer: Optimizing Erythrocyte Removal

  2026-05-20

  APExBIO's Red Blood Cell Lysis Buffer empowers researchers to achieve highly selective erythrocyte lysis, ensuring maximal recovery of nucleated cells for sensitive downstream analyses. This guide integrates workflow optimization, advanced research use-cases, and troubleshooting strategies, drawing on the latest findings in osteoblastic differentiation and cell isolation protocols.

• Trelagliptin Promotes Osteoblastic Differentiation via RUNX2

  2026-05-19

  This study demonstrates that trelagliptin, a DPP-4 inhibitor, enhances osteoblastic differentiation by upregulating RUNX2 through AMPK activation in MC3T3-E1 cells. These findings reveal a potential therapeutic avenue for osteoporosis and highlight the intersection of metabolic and bone biology.

524 records 6/35 page Previous Next First page 上5页 678910 下5页 Last page